Groningen, the Netherlands – March, 2026 – Innocore, a leading expert in advanced long-acting injectable drug delivery technologies, announces the start of a new development collaboration with a U.S.-based pharmaceutical company. The project further strengthens Innocore’s growing strategic presence in the United States and highlights the versatility of its proprietary drug delivery platform technologies.
The collaboration focuses on the development of a long-acting injectable formulation of a small molecule against depression, designed to provide steady predictable medication levels, improve patient convenience and treatment adherence through a ready-to-administer formulation. As a result, Innocore will identify the most suitable sustained-release approach for the intended therapy by evaluating both microsphere (MSP) and in situ forming depot (ISFD) technologies.
“This collaboration demonstrates how our formulation and polymer expertise can be applied in a wide range of therapeutic areas” said Hans de Backer, CEO of Innocore. “Our commitment to developing patient-friendly long-acting injectables that can improve convenience, adherence, and ultimately treatment outcomes goes beyond the obvious focus area of diabetes and obesity.”
The program also reflects the increasing interest from U.S.-based pharmaceutical companies in advanced drug delivery solutions which combine differentiated release profiles with scalable manufacturing and user-friendly injectable administrations.
Innocore’s proprietary SynBiosys® platform enables the development of tailored sustained-release formulations for complex therapeutics, including peptides, biologicals. The technology platform is designed to support tailored release kinetics while maintaining compatibility with sensitive active pharmaceutical ingredients and scalable manufacturing processes.
-Ends-
For more information, please contact: [email protected] About Innocore (Notes to Editors)
Innocore is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as diabetes, obesity, osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
Innocore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for clinical and commercial success. Innocore is innovating biologic drug formulation for better treatment outcomes and adherence.
For more information, please see: www.innocorepharma.com.